Pyxis Oncology Q3 net loss narrows as expenses fall

Overview

• US biopharma firm's Q3 net loss narrowed yr/yr as operating expenses declined

• Company closed $110 mln public offering in October, funding operations into H1 2028

• Pyxis highlighted progress in MICVO clinical program and plans for global Phase 3 trial

Outlook

• Pyxis Oncology plans to initiate global Phase 3 Headliner trial for MICVO in mid-2027

• FDA feedback on MICVO dose selection expected in Q1 2027

• Company expects cash on hand to fund operations into the first half of 2028

Result Drivers

• CLINICAL TRIAL EXPENSES - Co said higher clinical trial expenses for MICVO monotherapy and combination studies contributed to R&D costs in Q3

• MANUFACTURING COSTS - Lower manufacturing costs reduced R&D expenses compared to prior yr

• STOCK-BASED COMPENSATION - Lower stock-based compensation reduced general and administrative expenses yr/yr

Company press release:

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for Pyxis Oncology Inc is $7.50, about 351.8% above its November 4 closing price of $1.66

Reuters Recommended Reads

• Nov 4 - Solid Biosciences Q3 net loss widens on higher R&D costs

• Nov 4 - Lyell Immunopharma Q3 net loss widens on higher R&D spending

• Nov 4 - Dianthus Therapeutics Q3 net loss widens as clinical spending rises; sees MMN data in December

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)